Answers are grounded in this paper and cite their sources.
Real-world evidence shows urine osmolality improves tolvaptan dosing, reducing discontinuation rates in ADPKD patients, suggesting effective treatment management.
Urine osmolality is a practical and effective biomarker for guiding individualized tolvaptan titration in patients with ADPKD. This approach enabled adequate vasopressin suppression and was associated with a low discontinuation rate, supporting its use in real-world clinical practice.
No takes yet. Share an insight, caveat, or question.
Marn-Pernat et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: